WuXi Biologics reports strong revenue, profit growth in interim results

WuXi Biologics reported robust financial performance for the six months ended June 30, 2025, with revenue increasing by 16.1% year-on-year to RMB9,953.2 million. Gross profit saw a 27.0% increase to RMB4,252.9 million, expanding the gross profit margin to 42.7%. Net profit rose by 54.8% to RMB2,756.6 million, with net profit attributable to owners of the company climbing 56.0% to RMB2,339.3 million. Adjusted net profit increased by 11.6% to RMB2,839.9 million.

The group's total backlog reached $20.3 billion as of June 30, 2025, including $11.4 billion service backlog and $9.0 billion in potential milestone fees. Total assets grew 6.1% to RMB60,437.3 million, and total equity increased 7.9% to RMB49,065.0 million. Bank balances and cash stood at RMB8,439.0 million, up 1.9%.

Operationally, WuXi Biologics secured 86 new integrated projects, bringing the total to 864, including 429 pre-clinical and 344 early-phase projects. The company's CRDMO platform continues to expand globally, with new microbial manufacturing site construction in Chengdu and facility expansions in Ireland. The group completed two divestiture transactions, optimizing global operations and asset efficiency.